Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protease inhibitor therapy and bleeding.

J T Wilde1

  • 1West Midlands Adult Comprehensive Care Haemophilia Centre, University Hospital Birmingham NHS Trust, Edgbaston, Birmingham B15 2TH, UK. Jonathan.Wilde@university-b.wmids.nhs.uk

Haemophilia : the Official Journal of the World Federation of Hemophilia
|September 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous Bone Marrow Transplantation in Hodgkin's Disease-A Single Centre U.K. Experience.

Leukemia & lymphoma·2016
Same author

Didanosine treatment of haemophilic patients infected with HIV.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Hepatitis A immunization in HIV-infected haemophilic patients.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Update to UKHCDO guidance on vaccination against hepatitis A and B viruses in patients with inherited coagulation factor deficiencies and von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2013
Same author

Is it justifiable to transplant infected livers into haemophilia recipients?

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

The UK Haemophilia Doctors Organisation triennial audit of UK Comprehensive Care Haemophilia Centres.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same journal

Real-World Outcomes of Prophylaxis With rIX-FP in Germany: A Prospective, Non-Interventional Study in Haemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Prophylactic Factor Replacement Versus on-Demand Factor Replacement Following Primary Total Knee Arthroplasty in Patients With Hemophilia: A Retrospective Study With an Average 10-Year Follow-up.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Accuracy of Factor VIII Assays for Measuring Damoctocog Alfa Pegol: A Comparative Analysis.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Real-World Assessment of rVIII-SingleChain for Prophylactic Treatment in People With Severe Hemophilia A in High-Resource Settings.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Platelet Hyperreactivity May Contribute to Thrombotic Complications in Afibrinogenemia: A Case-Based Observation.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Predictors and Clinical Impact of Time to Diagnosis in Acquired Haemophilia A: An 11-Year Retrospective Cohort Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Protease inhibitor drugs (PIs) used for HIV treatment can increase bleeding risk in patients with hereditary bleeding disorders. This side effect may lessen over time, but its exact cause remains unknown.

Area of Science:

  • Pharmacology
  • Hematology
  • Infectious Diseases

Background:

  • Protease inhibitors (PIs) are crucial for managing human immunodeficiency virus (HIV) infection.
  • An observed association exists between PIs and an increased bleeding tendency in patients with hereditary bleeding disorders.

Purpose of the Study:

  • To describe the bleeding risks associated with protease inhibitor (PI) therapy in patients with hereditary bleeding disorders.
  • To highlight the clinical presentation, risk factors, and potential mechanisms of PI-induced bleeding.

Main Methods:

  • Observational analysis of clinical reports and patient data.
  • Review of existing literature on protease inhibitor adverse effects.

Main Results:

Related Experiment Videos

  • Increased frequency and unusual sites of bleeding (e.g., finger joints, mucous membranes, hematuria) were reported.
  • Ritonavir and indinavir showed higher bleeding risks; nelfinavir appeared lower.
  • PI-associated bleeds were often resistant to treatment and may necessitate prophylaxis.

    • Conclusions:

    • Protease inhibitor therapy presents a specific risk of bleeding in patients with hereditary bleeding disorders.
    • The mechanism is unclear, possibly involving a direct vascular effect rather than coagulation disturbances.
    • Awareness among clinicians and patients is crucial for managing this class-specific side effect.